García-Layana, AlfredoFigueroa, Marta SArias, LuisAraiz, JavierRuiz-Moreno, José MaríaGarcía-Arumí, JoséGómez-Ulla, FranciscoLópez-Gálvez, María IsabelCabrera-López, FranciscoGarcía-Campos, José ManuelMonés, JordiCervera, EnriqueArmadá, FélixGallego-Pinazo, Roberto2015-11-162015-11-162015-11García-Layana A, Figueroa MS, Arias L, Araiz J, Ruiz-Moreno JM, García-Arumí J, et al. Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. J Ophthalmol; 2015:4129032090-004Xhttp://hdl.handle.net/10668/2057Journal Article; Review;Individualized treatment regimens may reduce patient burden with satisfactory patient outcomes in neovascular age-related macular degeneration. Intravitreal anti-VEGF drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the patient is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that "treat and extend" and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing patient followup. Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a patient is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD patients in order to reduce the burden of specialized ophthalmologist services.enAnticuerpos monoclonales humanizadosDegeneración macularFactor A de crecimiento endotelial vascularAgudeza visualDegeneración macular húmedaProtocolos clínicosRecurrenciaHumanosMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, HumanizedMedical Subject Headings::Diseases::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular DegenerationMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Angiogenic Proteins::Vascular Endothelial Growth Factors::Vascular Endothelial Growth Factor AMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Ophthalmological::Vision Tests::Visual AcuityMedical Subject Headings::Diseases::Eye Diseases::Retinal Diseases::Retinal Degeneration::Macular Degeneration::Wet Macular DegenerationMedical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical ProtocolsMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::RecurrenceMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humansreview article26491550open access10.1155/2015/4129032090-0058PMC4600506